Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Diversifying crypto portfolios reduces concentration risk and smooths performance across market cycles. A varied mix helps you weather downturns while maintaining growth opportunities.
22,783 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Avis Budget Group stock surged this week as travel demand picked up and airport bottlenecks nudged customers toward r...
Markets rarely move in a straight line. This article analyzes the idea behind the prediction: trump bull market, what...
Geopolitical tensions push yields higher, nudging mortgage rates tick higher and complicating spring homebuying for m...
Super Micro Computer posted a margin-led earnings surprise that beat expectations and lifted full-year guidance, prom...
As the calendar moves into spring, the housing market shows mixed signals. This spring housing market update explains...
A notable stake in TowneBank marks a strategic bet by Patriot Financial Partners. This article breaks down what the i...
Many investors chase headline names, but a quiet stock nobody's talking about could surge as AI, data, and systems de...
A 50-year-old professional earning $210,000 unveils a four-account plan to craft tax-free retirement income by 62, bl...
A focused look at Toast's Q1 2026 results and what they imply for toast (tost) 2026 earnings. Expect discussion of re...
Tesla stock jumps about 19% in the past month, renewing the old Sell in May debate as summer trading looms and moment...
As the 2026 earnings season unfolds, investors want real, actionable insights on fidus (FDUS) 2026 earnings. This ana...